Chinese_Academy_of_Medical_Sciences_COVID-19_vaccine References

Chinese Academy of Medical Sciences COVID-19 vaccine
Vaccine description
Target	SARS-CoV-2
Vaccine type	Inactivated
Clinical data
Other names	Covidful ( Chinese: 科维福; pinyin: Kēwéifú)
Routes of; administration	Intramuscular
Legal status
Legal status	Emergency authorization: China ;
Identifiers
DrugBank	DB15863;

Chinese Academy of Medical Sciences COVID-19 vaccine, or IMBCAMS COVID-19 vaccine, traded as Covidful ( Chinese: 科维福; pinyin: Kēwéifú), is a COVID-19 vaccine developed by Institute of Medical Biology, Chinese Academy of Medical Sciences [ zh].

Clinical trials

In May 2020, Covidful started phase I/II clinical trial with 942 participants in China.^[2]

In January 2021, Covidful started phase III clinical trials with 34,020 from Brazil and Malaysia.^[3]

Full authorization

Emergency authorization

Allowed for travel

On 9 June 2021, The vaccine has been approved by the Chinese authorities.^[1]

^ ^a ^b Liu R, Woo R (9 June 2021). "China builds new plant for IMBCAMS COVID-19 vaccine -state media". Reuters. Retrieved 15 June 2021.
^ Clinical trial number NCT04412538 for "Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19" at ClinicalTrials.gov
^ Clinical trial number NCT04659239 for "The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19" at ClinicalTrials.gov